DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Anti-inflammatory effect of pimecrolimus in the sodium lauryl sulphate test.

Author(s): Engel K, Reuter J, Seiler C, Schulte Monting J, Jakob T, Schempp CM

Affiliation(s): Department of Dermatology, University Medical Center, Freiburg, Germany.

Publication date & source: 2008-04, J Eur Acad Dermatol Venereol., 22(4):447-50. Epub 2007 Nov 19.

Publication type: Randomized Controlled Trial; Research Support, Non-U.S. Gov't

BACKGROUND: Pimecrolimus is a calcineurin inhibitor used for the topical treatment of inflammatory skin diseases. We have shown previously that pimecrolimus cream is not effective on intact skin in the ultraviolet erythema test. OBJECTIVE: To test the anti-inflammatory effect of pimecrolimus cream after damage of the skin barrier by sodium lauryl sulphate (SLS) in a randomised, placebo-controlled, observer-blinded study. METHODS: SLS (3% v/v) was applied under occlusion on the back of 36 healthy volunteers for 24 h. Subsequently, the test areas were treated for 24 h with pimecrolimus cream, 1% hydrocortisone in a hydrophilic ointment, and the vehicle alone over three consecutive days. One control area remained untreated. The erythema index and the transepidermal water loss (TEWL) served as readout parameters to assess the SLS-induced skin irritation. RESULTS: Pimecrolimus cream and 1% hydrocortisone cream significantly reduced the SLS-induced erythema. The two test preparations did not have a significant effect on the TEWL. CONCLUSION: After damage to the skin barrier by SLS, pimecrolimus seems to penetrate into the skin as shown by a reduction of the irritation-induced erythma. These data further support the notion that pimecrolimus is selectively effective in the treatment of skin disorders with an impaired function of the epidermal barrier.

Page last updated: 2008-06-22

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017